1,721,761 research outputs found
Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer
No full textSmoking history effect on peripheral lung inflammation and gene transcription in chronic obstructive pulmonary disease
No full text--
Telithromycin in acute exacerbations of asthma
No full textComment on
Treating acute asthma with antibiotics--not quite yet. [N Engl J Med. 2006]
The effect of telithromycin in acute exacerbations of asthma. [N Engl J Med. 2006
Oxidants and asthma
No full textMany decades of research have produced a significant amount of data showing increased oxidative stress in asthma and indicating a potential role for oxidants in the pathogenesis of the disease, particularly during exacerbations. Putatively relevant pro-oxidative mechanisms have also been identified. Currently available asthma drugs are generally effective for the treatment of the disease, but their effects on oxidative stress have still not been completely elucidated. From the data available in the literature one can conclude that antioxidant compounds may have a potential role in the treatment of asthma, especially of asthma exacerbations. More convincing evidence from controlled clinical trials is required
Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review
No full textN-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; however, some clinical trials have studied the efficacy of NAC at higher doses. The aim of this review was to evaluate the adverse effects profile of NAC at higher than the standard dose in chronic respiratory diseases to establish a risk–benefit ratio in increasing the daily dose; therefore, studies using NAC at a dose of at least 600 mg/day were selected. Forty-one articles where NAC has been used at 600 mg and above, up to 3000 mg/day, and with a specific report on safety, were considered. Most of the studies used oral NAC and were conducted on patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, bronchiectasis, chronic bronchitis and cystic fibrosis. In general, the safety profile was similar at both the high and standard doses with the oral formulation; gastrointestinal symptoms were reported but they were no more common than in the control group
- …
